Dengue Fever Vaccines and Antivirals Market Size, Clinical Trials, Product Pipelines and Investment Trends, till 2032

Dengue Fever Vaccines and Antivirals Market Size is estimated to be $471 million in 2024 and is expected to grow at an average yearly rate of around 11% during the timeframe (2025-2032).

What is Dengue Fever Vaccines and Antivirals and what are the growth drivers of Dengue Fever Vaccines and Antivirals Market?

Dengue fever is a mosquito-borne viral infection that affects millions of people globally, particularly in tropical and subtropical regions. The disease is caused by four closely related dengue virus serotypes (DENV-1 to DENV-4), and infection with one serotype provides lifelong immunity to that serotype but not to the others. In recent years, there has been significant progress in the development of both vaccines and antiviral treatments to manage and prevent dengue fever. Dengue vaccines aim to provide protection against all four serotypes, while antivirals are designed to reduce the severity and duration of infection by targeting viral replication or the immune response.

Currently, the most notable vaccine available is a live attenuated tetravalent dengue vaccine that has been licensed in several countries. Other vaccine candidates, including recombinant subunit, DNA, and inactivated vaccines, are in various stages of development. On the antiviral front, research is ongoing to discover compounds that can effectively target viral components and halt disease progression. Although no specific antiviral therapy for dengue has been approved yet, supportive treatments and hospital care help manage symptoms and reduce complications.

Growth Drivers of Dengue Fever Vaccines and Antivirals Market

The market for dengue fever vaccines and antivirals is driven by a range of factors that reflect both the urgent public health need and the growing investment in infectious disease management.

High Disease Burden and Expanding Endemic Regions
The increasing incidence of dengue fever globally, with outbreaks becoming more frequent and severe, is a major growth driver. Climate change, urbanization, and global travel have contributed to the spread of dengue-carrying mosquitoes to new geographic areas. As a result, countries in Asia-Pacific, Latin America, Africa, and even some parts of Europe are experiencing rising case numbers, creating an expanding market for both vaccines and antiviral treatments.

Public Health Initiatives and Government Support
Governments and global health organizations are prioritizing dengue prevention due to its impact on public health systems and economies. Initiatives such as vaccination programs and mosquito control efforts are boosting demand for effective vaccines. Additionally, regulatory bodies are increasingly fast-tracking vaccine and antiviral approvals under emergency use or priority review pathways, which encourages research and commercial investment in the sector.

Advancements in Vaccine Technology and R&D Investment
Technological advancements in vaccine development, including novel platforms such as mRNA and vector-based vaccines, are enabling the creation of more effective and safer dengue vaccines. These innovations are shortening development timelines and improving immunogenicity across serotypes. The surge in research and development funding from both public and private sectors is further accelerating the discovery of antiviral agents, which enhances the growth potential of the market.

Rising Awareness and Preventive Healthcare Demand
Growing public awareness about dengue prevention and an increased focus on preventive healthcare are contributing to higher vaccination rates in endemic areas. Travel medicine is also gaining traction, with travelers to dengue-endemic regions seeking pre-travel vaccination, which expands the customer base beyond local populations.

Strategic Collaborations and Market Expansion Efforts
Pharmaceutical companies are entering strategic partnerships with research institutes, non-profits, and governments to co-develop and distribute dengue vaccines and antivirals. These collaborations are helping to enhance market penetration, reduce development costs, and streamline regulatory processes, further supporting market growth.



The research and analytics firm Datavagyanik released the updated version of its report on "Dengue Fever Vaccines and Antivirals Market - Detailed Analysis, Business Opportunities and Forecasts".

Request sample at https://datavagyanik.com/reports/dengue-fever-vaccines-and-antivirals-market/



Clinical Trials in Dengue Fever Vaccines and Antivirals Market and New Product Pipelines

The landscape of dengue vaccine development is dynamic, with multiple candidates advancing through clinical stages. Merck is spearheading a global Phase 3 trial (MOBILIZE‐1) for its single-dose tetravalent vaccine candidate V181. The trial is recruiting up to 12,000 participants aged 2-17 across Asia‐Pacific countries to evaluate immunogenicity, safety, and efficacy against all four dengue serotypes. If successful, V181 could simplify immunization logistics and broaden protection regardless of prior infection status.

Takeda's TAK‐003 (Qdenga), already prequalified by WHO and approved in many endemic regions, continues to undergo extensive Phase 3 post-marketing studies and long-term safety monitoring. Meanwhile, the NIH-developed TV‐003/005 live attenuated vaccine is in Phase 3 trials in Brazil and advanced Phase 2 studies in countries like India and Thailand, through collaborations with local manufacturers such as Instituto Butantan and Serum Institute.

At Butantan, another live attenuated vaccine is mid‐stream in Phase 3 testing, further expanding the live‐attenuated vaccine class. Other platforms such as recombinant subunit (Merck's V180) and inactivated or DNA-based vaccines are in early-phase trials, though none have yet progressed beyond Phase 2.

Antiviral Development: Progress in Clinical and Preclinical Pipelines

Dengue antivirals aim to provide therapeutic options for infected individuals. Novartis's NITD‐688 has shown strong preclinical efficacy-acting on viral proteins NS3/NS4B-and is now in Phase 2 clinical trials evaluating its antiviral activity in dengue patients. AbViro's AV‐1, a monoclonal antibody therapeutic, is entering a federally funded Phase 2 human dengue challenge study involving 84 participants, testing its ability to reduce viral load and symptoms.

Separately, AbViro is exploring AT‐752, an oral antiviral designed for dengue treatment. It has advanced into global Phase 2 trials (DEFEND‐2) as well as human challenge studies, with data suggesting promising antiviral effects. Another antiviral, Xafty-a niclosamide-based broad-spectrum candidate-has moved forward with clinical trials in Vietnam and partnerships between Hyundai Bioscience and DNDi aiming at affordable, accessible dengue treatment in low‐resource settings.

Notably, Johnson & Johnson halted development of its dengue antiviral candidate mosnodenvir (JNJ‐1802) after a Phase 2 field study, due to a shift in strategic priorities, despite some signal of antiviral activity.

Highlights of Key Pipeline Candidates

V181 (Merck): Single-dose, tetravalent live-attenuated vaccine in Phase 3; potential to simplify immunization campaigns.

TAK‐003 (Takeda): Approved WHO-prequalified vaccine; long-term Phase 3 and real-world evaluations underway.

TV‐003/005 (NIH/Butantan/Panacea Biotec): Live-attenuated vaccine entering Phase 3 in Brazil, leverage international production partnerships.

NITD‐688 (Novartis): Pan-serotype antiviral in Phase 2, directly targeting viral replication.

AV‐1 (AbViro): Monoclonal antibody therapeutic entering Phase 2 human challenge trials.

AT‐752 (AbViro): Oral antiviral in Phase 2 global and challenge studies; fast-tracked due to urgent need.

Xafty (Hyundai Bioscience/DNDi): Niclosamide-derived antiviral initiating clinical development, focusing on affordability and access.

Emerging Trends and Market Implications

The dengue pipeline reflects a robust expansion in both preventative and therapeutic approaches. Vaccine candidates are diversifying across platforms-live-attenuated, subunit, inactivated, and DNA-with an industry focus on single-dose schedules and broader serotype coverage. Antiviral development is gaining traction, with a shift from predominantly vaccine-centric strategies to combined prevention-and-treatment ecosystems.

Public-private partnerships and global health alliances are central to this momentum. Collaborations like NIH‐facilitated development of TV‐003/005 and Hyundai-DNDi's work on Xafty emphasize equitable access and deployment in endemic, resource-limited regions.

Regulatory acceleration mechanisms, such as WHO prequalification and fast‐track designations, are shortening timelines and enabling faster real-world impact. As candidates progress through late-stage trials, the next two to three years should reveal which solutions are viable for mass use.



Request for customization https://datavagyanik.com/reports/dengue-fever-vaccines-and-antivirals-market/



Important target segments driving the demand for Dengue Fever Vaccines and Antivirals Market

The market for dengue fever vaccines and antivirals is evolving rapidly, shaped by rising infection rates, expanding geographic spread, and advancements in medical research. Demand for these products is primarily being driven by specific target segments that either face a higher risk of infection or have the capacity to support widespread adoption. Understanding these target groups is crucial to assessing the growth potential and direction of the market.

Endemic Population in Tropical and Subtropical Regions

One of the largest and most critical target segments consists of people living in dengue-endemic regions, particularly in countries across Asia-Pacific, Latin America, Africa, and parts of the Middle East. These populations are frequently exposed to dengue-carrying mosquitoes due to climate conditions and limited access to vector control. Governments in these regions are under pressure to reduce the public health burden caused by recurring outbreaks, making mass immunization and affordable treatment strategies a top priority. This creates a sustained demand for both vaccines and antiviral solutions.

Children and Adolescents

Children and adolescents represent a high-risk group for dengue infection, often suffering more severe symptoms and complications compared to adults. This demographic is a primary focus of vaccination campaigns and clinical trials, especially in school-based immunization programs. Vaccines such as TAK-003 have been evaluated for use in children as young as four years old, indicating a strong market alignment with this group. The long-term benefits of protecting younger populations also contribute to growing public and governmental interest in early prevention.

Travelers and Military Personnel

International travelers heading to dengue-endemic regions form another important segment driving demand. This includes tourists, expatriates, aid workers, and business travelers who require preventive vaccination before departure. Similarly, military personnel deployed to tropical regions are at heightened risk due to prolonged exposure and limited medical infrastructure. The need for quick and reliable protection, often through single-dose vaccines, positions this group as a high-value target for vaccine developers.

Healthcare Providers and Hospitals

Hospitals and healthcare providers in dengue-prone areas play a central role in driving the uptake of both vaccines and antivirals. Their procurement decisions, treatment guidelines, and diagnostic capabilities directly influence market demand. As clinical management of dengue continues to improve, healthcare institutions are investing in new antiviral agents to treat infected patients, especially during outbreaks when hospitalizations surge. These settings also serve as key trial sites and launchpads for new therapies.

Government and Public Health Agencies

Government agencies are among the most influential buyers in the dengue prevention space. They coordinate national immunization programs, secure funding from international donors, and often negotiate bulk vaccine purchases. Public health agencies also implement awareness campaigns that boost vaccination rates and encourage early treatment-seeking behavior. As a result, they are critical to driving consistent and large-scale demand for dengue-related healthcare solutions.

International Organizations and NGOs

Global health organizations and non-governmental organizations working in low- and middle-income countries contribute significantly to demand by supporting vaccine rollout and treatment access. These institutions often fund or subsidize vaccine distribution in underserved communities, promote public education, and collaborate with pharmaceutical companies to ensure equitable access. Their involvement broadens market reach and enhances long-term sustainability for dengue vaccines and antiviral products.

Key Players in Dengue Fever Vaccines and Antivirals, Market Share

The dengue fever vaccines and antivirals market is competitive and growing, with several major pharmaceutical and biotechnology companies actively engaged in research, development, and commercialization. These companies play a critical role in shaping the market landscape through innovations, regulatory approvals, strategic partnerships, and global distribution efforts. The market is also supported by regional players, public health organizations, and academic institutions working in collaboration with the private sector.

Takeda Pharmaceutical Company

Takeda is one of the most prominent players in the dengue vaccine market, primarily due to the success of its vaccine TAK-003, marketed under the brand name Qdenga. This tetravalent live-attenuated vaccine has received approval in multiple countries, including those in Europe, Latin America, and Asia. It has also been prequalified by the World Health Organization (WHO), allowing it to be distributed through international procurement agencies. Takeda's strong global presence, ongoing clinical trials, and partnerships with health authorities position it as a market leader in the dengue vaccine space.

Sanofi

Sanofi was the first company to bring a dengue vaccine to market with Dengvaxia. Although initial adoption faced challenges due to concerns about safety in individuals who had not been previously infected, it remains an important product in dengue immunization programs, particularly for individuals with confirmed past infection. Sanofi continues to monitor and expand the application of Dengvaxia in line with updated regulatory guidelines. Its early mover advantage and existing global distribution networks give it a significant share in the market.

Merck & Co. (MSD)

Merck is actively developing its dengue vaccine candidate V181, which is currently in Phase 3 clinical trials. The vaccine is designed to be a single-dose, tetravalent formulation that provides broad protection regardless of previous infection status. If successful, Merck's entry into the market could disrupt current dynamics by offering a simpler and potentially more accessible immunization option. The company's research capabilities and regulatory experience position it as a future key player with high potential to capture market share.

Instituto Butantan

Brazil-based Instituto Butantan is a major regional contributor to the dengue vaccine effort. It is working in collaboration with the U.S. National Institutes of Health (NIH) to develop and commercialize the TV-003/TV-005 vaccine candidate, currently in advanced clinical stages. Instituto Butantan's efforts are focused on ensuring affordable vaccine access in Latin America, and its public health orientation gives it a strong role in regional immunization strategies.

AbViro

AbViro is an emerging biotech company focused on antiviral treatments for dengue. Its monoclonal antibody candidate AV-1 and oral antiviral AT-752 are progressing through Phase 2 trials. While not yet commercialized, AbViro's innovative pipeline and involvement in human challenge studies highlight its potential in the antiviral segment of the market. As demand for dengue treatment grows, AbViro is well-positioned to become a significant player.

Other Emerging Players

Companies like Bio Farma, Panacea Biotec, and Hyundai Bioscience are also contributing to the market through partnerships and early-stage product development. These firms, often backed by government funding or nonprofit collaborations, aim to provide cost-effective solutions for endemic regions.



Key Questions Answered in the Dengue Fever Vaccines and Antivirals market report:

What is the total global Dengue Fever Vaccines and Antivirals Sales, and how has it changed over the past five years?

What is Dengue Fever Vaccines and Antivirals investment trend?

Which countries have the highest Dengue Fever Vaccines and Antivirals, and what factors contribute to their dominance in the market?

How does Dengue Fever Vaccines and Antivirals Sales vary across key manufacturers, and what expansions have been observed recently?

What is the current global revenue generated from Dengue Fever Vaccines and Antivirals Sales, and how does it compare to previous years?

Which industries drive the highest demand for Dengue Fever Vaccines and Antivirals, and how is this demand expected to evolve in the next five years?

What are the major challenges impacting Dengue Fever Vaccines and Antivirals industry and supply chain operations across key markets?

How do government policies, environmental regulations, and trade restrictions affect Dengue Fever Vaccines and Antivirals and market dynamics?

Related Studies:

Potassium Channel Blocker Drugs (Class III) Market
https://datavagyanik.com/reports/potassium-channel-blocker-drugs-class-iii-market/

Calcium Channel Blockers for Arrhythmia (Class IV) Market
https://datavagyanik.com/reports/calcium-channel-blockers-for-arrhythmia-class-iv-market/

Intravitreal Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapies Market
https://datavagyanik.com/reports/intravitreal-anti-vascular-endothelial-growth-factor-anti-vegf-therapies-market/

Long-Acting Anti-VEGF Implants Market
https://datavagyanik.com/reports/long-acting-anti-vegf-implants-market/

Bispecific VEGF/Angiopoietin-2 (Ang-2) Inhibitors Market
https://datavagyanik.com/reports/bispecific-vegf-angiopoietin-2-ang-2-inhibitors-market/

IT Park, Dehradun, UK

Datavagyanik is a business intelligence firm with clients worldwide. We provide the right knowledge and advisory to business organizations and help them to grow and excel. We specialize in areas such as Pharmaceutical, Healthcare, Manufacturing, Consumer Goods, Materials & Chemicals and others. We specialize in market sizing, forecasting, supply chain analysis, supplier intelligence, import-export insights, market trend analysis and competitive intelligence.

Contact us:

Peter (Sales Head)
Phone: +1-330-440-0311
Website: https://datavagyanik.com/
Linkedin: https://www.linkedin.com/company/datavagyanik-business-intelligence-solutions/
Email: sales@datavagyanik.com

This release was published on openPR.